• Most Popular
  • Most Shared

Celgene to buy Pharmion for $2.9 billion

NEW YORK
Sun Nov 18, 2007 6:28pm EST

Stocks

   

NEW YORK (Reuters) - Biotechnology company Celgene Corp (CELG.O) has agreed to buy Pharmion Corp PHRM.O for about $2.9 billion in stock and cash to boost Celgene's push into the oncology field, the two companies said on Sunday.

Stocks  |  Mergers & Acquisitions

Under the terms of the deal, Celgene will acquire all the outstanding shares of Pharmion common stock for $72 per share, payable in a combination of cash and Celgene common stock. The deal is expected to close in the second quarter and be slightly dilutive to earnings in 2008 and accretive in 2009 and beyond.

(Reporting by Michael Flaherty; Editing by Braden Reddall)
Stocks
Mergers & Acquisitions


More from Reuters

Photo

Fox, Time Warner Cable ink deal to avoid blackout

NEW YORK (Reuters) - Time Warner Cable and News Corp's Fox Networks Group agreed to a brief extension of their current carriage contract late on Thursday to avoid a blackout that would have prevented 13 million U.S. homes from seeing TV shows like "The Simpsons" and "House" as well as college and NFL football games.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle